Ex-Naval Medical Officer & Merck Veteran Vlad Hogenhuis Describes Life In Leadership At GSK
Dr Vlad Hogenhuis, a Merck & Co. Inc. veteran who joined GlaxoSmithKline PLC in 2012, is currently responsible for the UK company's vast speciality franchise – formulating a global strategy for novel drug development and product launches in the areas of cardiovascular, neuroscience, immunology, oncology, infectious disease, dermatology and a small group of additional diseases. These are markets of significant potential and unmet need for patients, comprising over £280bn in total sales for 2015.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.